Immunopharmacology is the study of how drugs modify immune function, whether to suppress pathological inflammation, augment deficient immune responses, or redirect immune activity against cancer. A working understanding of the cellular architecture of innate and adaptive immunity is indispensable for predicting drug effects, anticipating toxicities, and interpreting the rapidly expanding landscape of biologic and small-molecule immune therapies.
Innate Immunity: First-Line Defense. The innate immune system provides immediate, non-antigen-specific defense against pathogens and tissue damage. Its cellular effectors include neutrophils, monocytes and macrophages, dendritic cells (DCs), natural killer (NK) cells, mast cells, basophils, and eosinophils. Neutrophils are the most abundant circulating leukocytes and the first cells recruited to sites of acute infection; they kill pathogens through phagocytosis, oxidative burst, degranulation, and neutrophil extracellular trap (NET) formation. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are the principal pharmacological regulators of neutrophil production and are used clinically to reverse chemotherapy-induced neutropenia and to mobilize hematopoietic stem cells.1
Monocytes, Macrophages, and Dendritic Cells. Monocytes circulate in the blood and differentiate into tissue macrophages and DCs upon migration into tissues. Macrophages are the central cellular mediators of chronic inflammation, phagocytosing pathogens and cellular debris, presenting antigens to T cells, and secreting a broad array of inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), and interleukin-12 (IL-12). The macrophage is the primary target cell for TNF-alpha inhibitors and IL-1 antagonists. Dendritic cells are the most potent antigen-presenting cells (APCs) and are the critical link between innate and adaptive immunity: after pathogen encounter, DCs undergo maturation, upregulate co-stimulatory molecules (CD80, CD86), and migrate to lymph nodes to present processed antigen to naive T cells. Abatacept and belatacept exploit the dendritic cell-T cell interface by blocking CD80 and CD86 co-stimulatory ligand interaction with CD28 (cluster of differentiation 28, co-stimulatory receptor on T cells) required for full T-cell activation.2
Natural Killer Cells. NK cells are innate lymphocytes that recognize and kill virus-infected cells and tumor cells without prior antigen sensitization. NK cell activation is governed by a balance of activating receptors (NKG2D, NKp46, DNAM-1) and inhibitory receptors that recognize major histocompatibility complex class I (MHC class I) molecules on target cells; tumor cells that downregulate MHC class I to evade cytotoxic T lymphocytes (CTLs) become vulnerable to NK cell killing. NK cells also mediate antibody-dependent cellular cytotoxicity (ADCC) through their Fc-gamma receptor III (CD16), which is the mechanism by which therapeutic monoclonal antibodies such as rituximab and trastuzumab recruit NK cells to kill opsonized target cells. Immunosuppressive drugs that broadly suppress lymphocyte function, including calcineurin inhibitors and corticosteroids, impair NK cell activity and contribute to vulnerability to viral infections in transplant recipients.1
Adaptive Immunity: T Cells. The adaptive immune system provides antigen-specific, immunological memory-generating responses through T lymphocytes and B lymphocytes. T cells develop in the thymus and are subdivided into functional subsets defined by their surface markers and effector functions. CD4-positive (CD4) helper T cells (Th cells) orchestrate immune responses by secreting cytokines that activate macrophages, stimulate B-cell antibody production, and recruit additional effector cells. CD4 T cells differentiate into distinct subsets including Th1 (producing interferon-gamma (IFN-gamma) and driving macrophage activation and cellular immunity against intracellular pathogens), Th2 (producing interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13), driving eosinophilic inflammation and IgE production in atopy and helminth immunity), Th17 (producing interleukin-17A (IL-17A) and interleukin-17F (IL-17F), driving neutrophilic inflammation at mucosal surfaces), and regulatory T cells or Tregs (producing interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta), suppressing immune responses and maintaining self-tolerance). The pharmacological targeting of specific T-cell subsets or their cytokine products defines the mechanism of biologic drugs including the interleukin-17 (IL-17) inhibitors (targeting Th17 output) and dupilumab (blocking the IL-4/interleukin-13 (IL-13) receptor used by Th2 cells).23
Cytotoxic T Cells and Immune Checkpoints. CD8-positive (CD8) cytotoxic T lymphocytes (CTLs) kill target cells presenting foreign or tumor-derived peptide on MHC class I molecules through perforin-granzyme cytotoxicity and Fas-FasL interaction. CTL (cytotoxic T lymphocyte) activation requires T-cell receptor (TCR) engagement with peptide-MHC class I, co-stimulatory signals, and cytokine support from CD4 Th1 cells. In chronic infection and in tumor microenvironments, CTLs can enter a state of functional exhaustion characterized by upregulation of inhibitory checkpoint receptors including programmed death-1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), LAG-3 (lymphocyte-activation gene 3), and TIM-3 (T-cell immunoglobulin and mucin-domain containing-3). The checkpoint inhibitor class of cancer immunotherapy drugs reverses this exhaustion by blocking PD-1 or CTLA-4, reinvigorating anti-tumor CTL responses. This mechanism and its immune-related adverse events are covered comprehensively in Chapter 34 (ACD2-04); the foundational biology is introduced here because it is essential for understanding the broader framework of immune regulation.
B Cells and Antibody-Mediated Immunity. B lymphocytes are the effectors of humoral immunity. Upon antigen encounter and CD4 T-cell help (specifically through CD40L-CD40 (CD40 ligand-CD40) interaction and cytokine signals), B cells proliferate, undergo somatic hypermutation and class-switch recombination in germinal centers, and differentiate into plasma cells that secrete antigen-specific immunoglobulins. The five immunoglobulin classes (IgG, IgM, IgA, IgE, IgD) have distinct effector functions: IgG mediates opsonization, ADCC, and complement activation; IgE drives mast cell and basophil degranulation in allergy; IgA provides mucosal immunity. Pharmacological targeting of B cells includes anti-CD20 monoclonal antibodies (rituximab, obinutuzumab) that deplete B cells by complement-dependent cytotoxicity and ADCC, anti-BAFF/BLyS therapy (belimumab) that reduces B-cell survival factor and is used in systemic lupus erythematosus (SLE), and intravenous immunoglobulin (IVIG) that modulates Fc receptor signaling and complements endogenous antibody deficiency.4
Neutrophils: G-CSF (filgrastim), GM-CSF (sargramostim). Macrophages/monocytes: TNF-alpha inhibitors, IL-1 antagonists, IL-6 inhibitors, corticosteroids. Dendritic cells/co-stimulation: abatacept, belatacept. T cells (broad): calcineurin inhibitors, mTOR inhibitors, corticosteroids, azathioprine, mycophenolate. Th2/eosinophils: dupilumab (IL-4R), mepolizumab/benralizumab (IL-5 axis). Th17: secukinumab, ixekizumab (IL-17A), guselkumab, risankizumab (IL-23). B cells: rituximab (anti-CD20), belimumab (anti-BAFF), IVIG. CTLs: JAK inhibitors (via cytokine signaling modulation); checkpoint inhibitors (restore exhausted CTLs — see Ch34).
The innate immune system detects pathogens and tissue damage through a family of germline-encoded pattern recognition receptors (PRRs) that recognize conserved molecular patterns not present in healthy host cells. These receptors and their downstream signaling cascades are not only the mechanistic basis of the initial inflammatory response but are also direct or indirect targets of several pharmacological agents, including biologic drugs targeting inflammasome-derived cytokines and adjuvants that exploit pattern recognition receptor (PRR) signaling to enhance vaccine immunogenicity.
Toll-Like Receptors. Toll-like receptors (TLRs) are the best-characterized PRR family, consisting of 10 functional members in humans (TLR1 through TLR10). TLRs are type I transmembrane receptors expressed on the surface and in endosomal compartments of innate immune cells including macrophages, DCs, neutrophils, and mast cells, as well as on epithelial and endothelial cells. Each TLR (toll-like receptor) recognizes a distinct class of pathogen-associated molecular pattern (PAMP): TLR4 (toll-like receptor 4) recognizes lipopolysaccharide (LPS) from gram-negative bacteria in complex with MD-2 (myeloid differentiation factor 2) and CD14 (cluster of differentiation 14); TLR2 (toll-like receptor 2) forms heterodimers with TLR1 (recognizing triacylated lipopeptides) or TLR6 (recognizing diacylated lipopeptides); TLR3 (toll-like receptor 3) recognizes double-stranded RNA (dsRNA) from viral replication; TLR7 (toll-like receptor 7) and TLR8 (toll-like receptor 8) recognize single-stranded RNA (ssRNA); TLR9 (toll-like receptor 9) recognizes unmethylated CpG dinucleotides in bacterial and viral deoxyribonucleic acid (DNA). All TLRs signal through Toll/interleukin-1 (IL-1) receptor (TIR) domain-containing adaptor proteins, primarily MyD88, leading to activation of nuclear factor kappa B (NF-kB) and mitogen-activated protein kinases (MAPKs), and ultimately to transcription of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), IL-1 beta, interleukin-6 (IL-6), and interleukin-12 (IL-12).5
TLRs as Drug Targets and Vaccine Adjuvants. TLR signaling is a pharmacologically relevant target from two opposing directions. First, excessive or dysregulated TLR activation drives inflammatory diseases, and TLR4 signaling in particular has been implicated in sepsis pathophysiology, atherosclerosis, and non-alcoholic steatohepatitis. Pharmacological TLR4 antagonism has been an active area of drug development, though clinical success in sepsis has been limited. Second, TLR agonists are exploited as vaccine adjuvants to enhance adaptive immune responses. Monophosphoryl lipid A (MPL-A), a detoxified TLR4 agonist derived from Salmonella minnesota LPS, is a component of the AS01B (Adjuvant System 01B) adjuvant system used in the recombinant zoster vaccine (Shingrix) and in the malaria vaccine (RTS,S/AS01); AS01B combines MPL-A with the saponin QS-21 (quillaja saponaria fraction 21) to produce a potent Th1-biased adaptive immune response. CpG-1018, a synthetic TLR9 agonist oligonucleotide, is the adjuvant in the hepatitis B vaccine HEPLISAV-B (hepatitis B surface antigen vaccine with CpG adjuvant) and produces substantially higher seroconversion rates compared to aluminum-only adjuvanted hepatitis B vaccines, particularly in immunocompromised patients and older adults.56
NLRs and the Inflammasome. Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are cytoplasmic PRRs that sense intracellular danger signals. The most clinically relevant NOD-like receptor (NLR) is NLRP3 (NOD-, leucine-rich repeat (LRR)-, and pyrin domain-containing protein 3), which forms the NLRP3 inflammasome, a multiprotein complex that activates caspase-1, which in turn cleaves pro-IL-1 beta and pro-IL-18 into their biologically active secreted forms. NLRP3 is activated by a broad range of danger signals including extracellular ATP (released from damaged cells), monosodium urate (MSU) crystals in gout, calcium pyrophosphate crystals in pseudogout, cholesterol crystals in atherosclerotic plaques, silica and asbestos fibers, and oxidized low-density lipoprotein (oxLDL). The NLRP3 inflammasome is therefore a mechanistic convergence point linking cellular damage and metabolic dysregulation to IL-1 beta-driven inflammation. This pharmacological logic underlies the use of IL-1 antagonists (anakinra, canakinumab) in crystal arthropathies, the Cryopyrin-associated periodic syndromes, CAPS (caused by gain-of-function NLRP3 mutations), and the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial use of canakinumab for secondary cardiovascular event prevention.7
Damage-Associated Molecular Patterns. Beyond PAMPs derived from pathogens, innate immune cells also respond to damage-associated molecular patterns (DAMPs) released from necrotic or stressed host cells. Key DAMPs include high mobility group box 1 protein (HMGB1), heat shock proteins, uric acid crystals, extracellular ATP, and cell-free DNA. DAMPs signal through the same PRRs as PAMPs, particularly TLR2, TLR4, TLR9, and the NLRP3 inflammasome, initiating sterile inflammation in settings such as myocardial infarction, trauma, ischemia-reperfusion injury, and autoimmune flares. The concept of sterile inflammation driven by DAMPs is relevant to understanding why immunosuppressive drugs effective in autoimmunity may also reduce cardiovascular inflammatory risk, as demonstrated in the CANTOS trial, where IL-1 beta inhibition with canakinumab reduced recurrent major adverse cardiovascular events in patients with prior myocardial infarction and elevated high-sensitivity C-reactive protein (hsCRP), independent of lipid lowering.37
RIG-I-Like Receptors and Cytosolic DNA Sensors. RIG-I (retinoic acid-inducible gene I) and MDA5 (melanoma differentiation-associated protein 5) are cytosolic RNA helicases that detect dsRNA generated during viral replication in the cytoplasm, signaling through the mitochondrial adaptor MAVS (mitochondrial antiviral signaling protein) to activate interferon regulatory factor 3 (IRF3) and IRF7 (interferon regulatory factor 7), driving transcription of type I interferons (IFN-alpha and IFN-beta). The cytosolic DNA sensor cGAS (cyclic GMP-AMP synthase) detects double-stranded DNA (dsDNA) and produces the second messenger cGAMP, which activates STING (stimulator of interferon genes), also leading to type I IFN production. These pathways are relevant to immunopharmacology in several ways: constitutive activation of STING by self-DNA drives autoinflammatory and autoimmune diseases such as STING-associated vasculopathy with onset in infancy (SAVI) and Aicardi-Goutieres syndrome; STING agonists are in clinical development as cancer immunotherapy adjuvants; and the mRNA vaccine platform activates these innate sensing pathways, contributing to the immunogenicity of mRNA-lipid nanoparticle (LNP) vaccines.6
NLRP3 inflammasome activation drives IL-1 beta secretion in gout (MSU crystals), CAPS (NLRP3 gain-of-function mutations), Still's disease, and atherosclerosis (cholesterol crystals). Anakinra (recombinant IL-1Ra): blocks IL-1alpha and IL-1beta receptor binding; short half-life, daily SC injection; used in gout flares refractory to colchicine/NSAIDs, CAPS, Still's disease, COVID-19 cytokine storm (off-label). Canakinumab (anti-IL-1beta monoclonal antibody): long half-life, monthly or quarterly dosing; approved for CAPS, systemic JIA, gout; CANTOS trial showed 15% relative risk reduction in MACE at 150 mg dose. Rilonacept (IL-1 trap): soluble decoy receptor for IL-1alpha and IL-1beta; approved for CAPS and recurrent pericarditis.
Cytokines are low-molecular-weight soluble proteins that act as intercellular messengers coordinating immune responses. They act in autocrine, paracrine, and endocrine fashion through specific cell-surface receptors linked to intracellular signaling cascades. The pharmacological targeting of individual cytokines or their receptors now constitutes one of the largest and most rapidly expanding classes of therapeutic agents in medicine, with approved drugs spanning rheumatology, gastroenterology, dermatology, pulmonology, hematology, and oncology.
Tumor Necrosis Factor-Alpha: The Prototypic Inflammatory Cytokine. Tumor necrosis factor-alpha (TNF-alpha) is a pleiotropic cytokine produced primarily by activated macrophages and T cells in response to infection, tissue injury, and autoimmune stimuli. It exists as a membrane-bound homotrimer and a soluble cleaved form; both are biologically active. TNF-alpha signals through two receptors: TNF receptor 1 (TNFR1), which is ubiquitously expressed and mediates the majority of inflammatory and apoptotic signaling, and TNF receptor 2 (TNFR2), which is expressed primarily on immune cells and endothelial cells. Downstream signaling activates nuclear factor kappa B (NF-kB), driving transcription of additional inflammatory cytokines, adhesion molecules, and acute-phase proteins. TNF-alpha is central to the pathogenesis of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, ankylosing spondylitis (AS), and psoriatic arthritis (PsA). Five TNF-alpha inhibitors are approved: infliximab (chimeric IgG1 monoclonal antibody), adalimumab (fully human IgG1), golimumab (fully human IgG1), certolizumab pegol (pegylated Fab fragment without Fc region), and etanercept (dimeric fusion protein of TNFR2 extracellular domain with IgG1 Fc). Structural differences have clinical consequences: certolizumab lacks the Fc region and therefore does not cross the placenta via FcRn-mediated transport, making it the preferred TNF inhibitor in pregnancy; etanercept binds both TNF-alpha and TNF-beta (lymphotoxin-alpha) and may have a different infection risk profile compared to monoclonal antibody TNF inhibitors.8
IL-1 Family. Interleukin-1 (IL-1) comprises two agonist cytokines, IL-1 alpha and IL-1 beta, and a naturally occurring antagonist, IL-1 receptor antagonist (IL-1Ra). IL-1 alpha is primarily cell-associated and acts as a damage-associated molecular pattern (DAMP) when released from necrotic cells. IL-1 beta is synthesized as an inactive precursor (pro-IL-1 beta) and is cleaved to its active form by caspase-1 within the inflammasome. Both agonists signal through the same receptor complex, IL-1 receptor type I (IL-1RI) with its co-receptor IL-1 receptor accessory protein (IL-1RAcP), activating MyD88, IL-1 receptor-associated kinase (IRAK), TNF receptor-associated factor 6 (TRAF6), and ultimately nuclear factor kappa B (NF-kB). IL-1Ra competes with IL-1 alpha and IL-1 beta for IL-1RI binding but does not activate signaling. IL-1 beta is a potent endogenous pyrogen (fever inducer) acting on the hypothalamus, and it stimulates hepatic acute-phase protein synthesis including C-reactive protein (CRP) and serum amyloid A. Pharmacological targeting includes anakinra (recombinant IL-1Ra that blocks both IL-1 alpha and IL-1 beta), canakinumab (monoclonal antibody selective for IL-1 beta), and rilonacept (dimeric fusion protein of IL-1RI and IL-1RAcP extracellular domains that acts as a soluble decoy receptor for both IL-1 alpha and IL-1 beta).7
IL-6 and the Acute-Phase Response. Interleukin-6 (IL-6) is produced by macrophages, T cells, fibroblasts, and endothelial cells and acts on virtually all tissues through the IL-6 receptor (IL-6R) complex comprising the ligand-binding IL-6R alpha chain (CD126) and the signal-transducing gp130 subunit (CD130). IL-6 can signal in two distinct modes: classical signaling through membrane-bound IL-6R (expressed mainly on hepatocytes and leukocytes), and trans-signaling through soluble IL-6R (sIL-6R) shed from cell surfaces, which allows IL-6 to signal on virtually any cell expressing gp130. Trans-signaling is believed to mediate many of the pro-inflammatory systemic effects of IL-6. IL-6 drives hepatic synthesis of acute-phase reactants (fibrinogen, hepcidin, CRP), induces fever through the hypothalamic prostaglandin E2 pathway, stimulates megakaryocyte differentiation (contributing to thrombocytosis in chronic inflammation), promotes Th17 differentiation in combination with transforming growth factor-beta (TGF-beta), and inhibits Treg development. IL-6 blockade with tocilizumab (anti-IL-6R monoclonal antibody) or sarilumab (anti-IL-6R) suppresses CRP so effectively that CRP cannot be used as an infection biomarker in patients receiving these drugs, a critical safety consideration that distinguishes them from TNF inhibitors.9
IL-2 and T-Cell Proliferation. Interleukin-2 (IL-2) is produced primarily by activated CD4-positive (CD4) T cells and is the principal autocrine and paracrine growth factor for T lymphocytes. It signals through a trimeric receptor complex comprising the interleukin-2 receptor (IL-2R) alpha chain (the high-affinity IL-2R subunit known as CD25), the IL-2R beta chain (CD122), and the common gamma chain (cluster of differentiation 132, CD132), shared with interleukin-4 (IL-4), interleukin-7 (IL-7), interleukin-9 (IL-9), interleukin-15 (IL-15), and interleukin-21 (IL-21) receptors. Downstream signaling activates Janus kinase 1 (JAK1) and JAK3 (associated with the beta and gamma-c chains respectively), signal transducer and activator of transcription 5 (STAT5), and the phosphoinositide 3-kinase-protein kinase B (PI3K-AKT)-mTOR pathway. IL-2 signaling is bidirectional in its immune effects: at low concentrations it drives Treg expansion (Tregs constitutively express high-affinity IL-2R including CD25 and are exquisitely sensitive to IL-2), while at high concentrations it drives effector T-cell and natural killer (NK) cell expansion. Pharmacological exploitation of IL-2 spans the full spectrum: high-dose recombinant IL-2 (aldesleukin) is used for metastatic renal cell carcinoma (RCC) and melanoma immunotherapy but causes severe vascular leak syndrome; calcineurin inhibitors suppress IL-2 gene transcription as their primary mechanism of immunosuppression; and low-dose IL-2 is in clinical development as a Treg-selective immunosuppressive strategy in autoimmune disease.10
Type 2 Cytokines and Targeted Therapies. The type 2 immune response, driven by Th2 cells and type 2 innate lymphoid cells, is characterized by secretion of interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13) and mediates host defense against helminths and drives allergic disease. IL-4 promotes IgE class switching in B cells and drives Th2 differentiation of naive CD4 T cells; it signals through IL-4R alpha (IL-4Ralpha) paired with the gamma-c chain (type I IL-4R) or with interleukin-13 receptor (IL-13R) alpha 1 (type II IL-4R, which also binds IL-13). IL-5 is the principal regulator of eosinophil production, maturation, activation, and survival; it signals through the IL-5R (interleukin-5 receptor) alpha/beta-c receptor complex. IL-13 shares the type II receptor with IL-4 and drives mucus hypersecretion, smooth muscle hyperreactivity, and fibrosis in the airways. Dupilumab, a monoclonal antibody targeting IL-4Ralpha, blocks both IL-4 and IL-13 signaling and is approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis. Mepolizumab and reslizumab (anti-IL-5), benralizumab (anti-IL-5Ralpha), and tezepelumab (anti-thymic stromal lymphopoietin, TSLP) are approved for severe eosinophilic asthma.11
Interleukin-12 (IL-12), IL-23, IL-17, and the Th17 Axis. The IL-12/interleukin-23 (IL-23)/interleukin-17 (IL-17) axis is central to inflammatory responses at epithelial surfaces and the pathogenesis of psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Interleukin-12 (IL-12) is a heterodimeric cytokine (p35/p40 subunits) produced by DCs and macrophages that drives Th1 differentiation and interferon-gamma (IFN-gamma) production. IL-23 shares the p40 subunit with IL-12 but pairs it with p19; it is produced by DCs and macrophages and drives the expansion and survival of Th17 cells. Interleukin-17A (IL-17A) and interleukin-17F (IL-17F), produced by Th17 cells and type 3 innate lymphoid cells, stimulate epithelial cells, fibroblasts, and stromal cells to produce IL-6, interleukin-8 (IL-8), G-CSF, and matrix metalloproteinases, driving neutrophilic inflammation and tissue remodeling.12
Biologic Agents Targeting the IL-12, IL-23, and IL-17 Pathways. Ustekinumab targets the p40 subunit shared by IL-12 and IL-23, thus blocking both cytokines simultaneously, and is approved for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis (UC). Selective IL-23p19 inhibitors (guselkumab, risankizumab, tildrakizumab) have superseded ustekinumab in many psoriasis algorithms due to superior efficacy and durability. IL-17A inhibitors (secukinumab, ixekizumab) and the dual interleukin-17A/interleukin-17F (IL-17A/IL-17F) inhibitor bimekizumab are among the most effective treatments for moderate-to-severe plaque psoriasis and are first-line biologics for ankylosing spondylitis, though IL-17 blockade carries a class-specific risk of new-onset or worsening IBD and is contraindicated or used with extreme caution in patients with active IBD.12
IFN-gamma and Interleukin-10 (IL-10). Interferon-gamma (IFN-gamma) is the signature Th1 cytokine, produced by CD4 Th1 cells, CD8-positive (CD8) cytotoxic T lymphocytes (CTLs), and natural killer (NK) cells. It activates macrophages to a bactericidal and tumoricidal state (classical or M1 activation), upregulates major histocompatibility complex class I (MHC class I) and class II expression on virtually all nucleated cells and antigen-presenting cells (APCs) respectively, and promotes Th1 over Th2 differentiation. IFN-gamma is essential for host defense against intracellular pathogens; deficiencies in IFN-gamma signaling (as in genetic defects in the IFN-gamma receptor or in its downstream signal transducer STAT1 (signal transducer and activator of transcription 1)) result in susceptibility to mycobacterial disease and other intracellular infections. Recombinant IFN-gamma (interferon gamma-1b) is approved for the prevention of serious infections in chronic granulomatous disease (CGD) and for slowing disease progression in severe malignant osteopetrosis.1 IL-10 is a regulatory cytokine produced by macrophages, Tregs, and other cells that suppresses macrophage activation, inhibits pro-inflammatory cytokine production, and promotes tolerance. IL-10 acts through JAK1/TYK2-STAT3 (Janus kinase 1/tyrosine kinase 2-signal transducer and activator of transcription 3) signaling and is essential for maintaining intestinal homeostasis; IL-10 or IL-10 receptor loss-of-function mutations cause severe early-onset IBD. Paradoxically, recombinant IL-10 failed in clinical trials for IBD, likely because systemic IL-10 administration also stimulates NK cells and has unintended pro-inflammatory effects.9
TNF-alpha: infliximab, adalimumab, etanercept, certolizumab, golimumab. IL-1 alpha/beta: anakinra; IL-1 beta only: canakinumab; IL-1 trap: rilonacept. IL-6R: tocilizumab, sarilumab; IL-6 ligand: siltuximab. IL-4Ralpha (IL-4+IL-13 block): dupilumab. IL-5: mepolizumab, reslizumab; IL-5Ralpha: benralizumab. IL-12/23 p40: ustekinumab. IL-23 p19: guselkumab, risankizumab, tildrakizumab. IL-17A: secukinumab, ixekizumab; IL-17A+F: bimekizumab. IL-2 (high-dose stimulation): aldesleukin. IFN-gamma (stimulation): interferon gamma-1b.
The Janus kinase (JAK) family of non-receptor tyrosine kinases transduces signals from over 50 cytokines and growth factors through a shared intracellular signaling mechanism. Because so many immunologically important cytokines converge on Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling, JAK inhibitors represent a uniquely broad-spectrum approach to immune modulation, with the potential to suppress multiple cytokine pathways simultaneously through a single small molecule. Understanding isoform-specific JAK coupling to cytokine receptors is essential for predicting both the therapeutic effects and the toxicity profiles of individual JAK inhibitors.
JAK Family Members and Structural Biology. The JAK family comprises four members: JAK1 (Janus kinase 1), JAK2 (Janus kinase 2), JAK3 (Janus kinase 3), and TYK2 (tyrosine kinase 2). All four share a common domain architecture including an N-terminal 4.1 protein/ezrin/radixin/moesin (FERM) domain (mediating receptor association), a Src homology 2 (SH2) domain, a pseudokinase domain (JAK homology 2, JH2) that regulates kinase activity, and a C-terminal active kinase domain (JH1). The pseudokinase domain acts as an autoinhibitory regulatory domain; mutations in JH2 that relieve autoinhibition cause constitutive JAK activation and are responsible for several myeloproliferative neoplasms. The JAK2 V617F (valine-to-phenylalanine at position 617) point mutation, present in greater than 95% of polycythemia vera cases and approximately 50% of essential thrombocythemia and primary myelofibrosis cases, activates JAK2-STAT5 (JAK2-signal transducer and activator of transcription 5) signaling constitutively and is the molecular target of ruxolitinib and fedratinib in myeloproliferative disease.13
Cytokine Receptor-JAK Coupling. Cytokine receptors lack intrinsic kinase activity and instead associate constitutively with specific JAK family members. Upon cytokine binding, receptor subunits dimerize or oligomerize, bringing their associated JAKs into proximity, which leads to JAK trans-phosphorylation and activation. Activated JAKs then phosphorylate tyrosine residues in the receptor cytoplasmic tail, creating docking sites for STAT (signal transducer and activator of transcription) proteins. The specific JAKs involved depend on the receptor subunit composition: the gamma-c chain (shared by interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-7 (IL-7), interleukin-9 (IL-9), interleukin-15 (IL-15), and interleukin-21 (IL-21) receptors) is constitutively associated with JAK3; interleukin-6 (IL-6) and related cytokines signal through gp130 associated with JAK1 and JAK2; interferon-alpha (IFN-alpha) and IFN-beta signal through IFNAR1 (TYK2) and IFNAR2 (JAK1); IFN-gamma signals through IFNGR1 (JAK1) and IFNGR2 (JAK2); erythropoietin (EPO), thrombopoietin (TPO), and growth hormone signal through JAK2 homodimers. This coupling specificity defines the therapeutic consequences of JAK isoform selectivity.1314
STAT Transcription Factors. Seven signal transducer and activator of transcription (STAT) family proteins mediate JAK-dependent gene transcription; the family has seven members: signal transducer and activator of transcription 1 (STAT1), signal transducer and activator of transcription 2 (STAT2), signal transducer and activator of transcription 3 (STAT3), signal transducer and activator of transcription 4 (STAT4), STAT5a, STAT5b, and signal transducer and activator of transcription 6 (STAT6), each with distinct cytokine-receptor pairings. Upon JAK activation, STATs are recruited to phosphorylated receptor docking sites, phosphorylated on a conserved tyrosine residue, dimerize, translocate to the nucleus, and bind specific promoter elements called gamma-activated sequence (GAS) elements or interferon-stimulated response elements (ISREs). Key STAT-cytokine pairings of pharmacological relevance include: STAT1 (IFN-alpha, IFN-beta, IFN-gamma activation, drives antiviral and pro-inflammatory gene programs); STAT2 (IFN-alpha/beta type I IFN signaling); STAT3 (IL-6, interleukin-10 (IL-10), interleukin-11 (IL-11), oncostatin M, leukemia inhibitory factor (LIF) signaling, drives acute-phase response and anti-inflammatory programs; also constitutively activated in many cancers); STAT4 (interleukin-12 (IL-12) and interleukin-23 (IL-23), driving Th1 differentiation and IFN-gamma production); STAT5 (IL-2, IL-7, IL-15, EPO, TPO, prolactin, driving T-cell and hematopoietic cell survival and proliferation); and STAT6 (IL-4 and interleukin-13 (IL-13), driving Th2 differentiation, IgE class switching, and alternative macrophage activation).14
JAK Inhibitor Selectivity Profiles and Clinical Consequences. All approved JAK inhibitors are adenosine triphosphate (ATP)-competitive kinase inhibitors that bind the kinase active site. Although no approved JAK inhibitor is perfectly isoform-selective at clinical doses, the relative selectivity profiles of different inhibitors predict their clinical applications and toxicity patterns. Tofacitinib preferentially inhibits JAK1 and JAK3 (and to a lesser extent JAK2), thereby blocking gamma-c-chain cytokine signaling (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) and gp130 signaling (IL-6), with relative sparing of JAK2-dependent hematopoietic growth factor signaling; it is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC), and polyarticular juvenile idiopathic arthritis (pJIA). Baricitinib preferentially inhibits JAK1 and JAK2, providing broader cytokine suppression including IFN pathways; it is approved for RA, atopic dermatitis, and coronavirus disease 2019 (COVID-19) hospitalized patients requiring supplemental oxygen. Upadacitinib is a more selective JAK1 inhibitor with somewhat greater relative selectivity than tofacitinib, approved for RA, PsA, ankylosing spondylitis (AS), atopic dermatitis, UC, and Crohn's disease. Ruxolitinib preferentially inhibits JAK1 and JAK2 and is used in myeloproliferative neoplasms (polycythemia vera, myelofibrosis), graft-versus-host disease (GvHD), and atopic dermatitis (topical formulation). TYK2-selective inhibition with deucravacitinib blocks IL-12, IL-23, and type I IFN signaling while sparing JAK1, JAK2, and JAK3, offering a more restricted cytokine inhibition profile with potentially fewer off-target hematopoietic and metabolic effects.1415
JAK Inhibitor Safety: Black Box Warnings and Clinical Monitoring. The FDA issued a class-wide black box warning for JAK inhibitors based on the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance safety trial of tofacitinib in RA patients aged 50 years or older with at least one cardiovascular risk factor. Compared to tumor necrosis factor (TNF) inhibitors, tofacitinib was associated with a significantly higher incidence of major adverse cardiovascular events (MACE), malignancies (particularly lung cancer and lymphoma), venous thromboembolism (VTE) including deep vein thrombosis and pulmonary embolism, and all-cause mortality. The VTE risk is a class-wide concern across JAK inhibitors and is mechanistically attributed to inhibition of JAK2-dependent thrombopoietin signaling (altering platelet function) and potentially to suppression of STAT3-mediated anticoagulant gene transcription. All approved JAK inhibitors carry warnings for serious infections (including tuberculosis reactivation, opportunistic infections, and herpes zoster reactivation), malignancy, and VTE, and are indicated as second-line therapy after failure of one or more disease-modifying antirheumatic drugs (DMARDs) in RA and other approved indications. Screening for latent tuberculosis and hepatitis B before initiation is mandatory, paralleling the requirements for biologic TNF inhibitors.15
Based on ORAL Surveillance trial data (tofacitinib vs. TNF inhibitor in high-CV-risk RA): (1) Serious infections including opportunistic infections and TB reactivation. (2) Malignancy — lung cancer, lymphoma, and other malignancies reported at higher rates than TNF inhibitors in high-risk populations. (3) Major adverse cardiovascular events (MACE) — nonfatal myocardial infarction, nonfatal stroke, CV death. (4) Thrombosis — deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thrombosis. (5) Mortality. Restrict use to patients who have had inadequate response to TNF inhibitors. Mandatory pre-treatment screening: latent TB (TST or IGRA), hepatitis B surface antigen and core antibody, CBC with differential, lipid panel.
The complement system is a cascade of over 30 plasma and membrane-associated proteins that provides immediate effector functions against pathogens and opsonizes targets for phagocytosis. It is activated through three distinct pathways that converge at the central complement component C3 (complement component 3), and its terminal pathway forms the membrane attack complex (MAC). Dysregulated complement activation drives several severe human diseases, and pharmacological complement inhibition has emerged as a transformative strategy in rare hematologic, renal, and neurological conditions.
Complement Activation Pathways. The classical pathway is activated by C1q binding to IgG or IgM antibodies bound to antigen surfaces, or directly to certain pathogens and apoptotic cells. C1q binding activates the C1r and C1s serine proteases, which cleave C4 (complement component 4) and C2 (complement component 2) to form the classical pathway C3 convertase (C4b2a). The lectin pathway is activated when mannose-binding lectin (MBL) or ficolins bind carbohydrate patterns on pathogen surfaces, activating MBL-associated serine proteases (MASPs) to form the same C4b2a convertase. The alternative pathway is constitutively active at a low level through spontaneous hydrolysis of C3 (C3 tickover), and is amplified when C3b deposits on pathogen surfaces and recruits factor B (cleaved by factor D to form the alternative pathway C3 convertase, C3bBb, stabilized by properdin). All three pathways converge at C3 cleavage: C3 convertases cleave C3 into C3a (an anaphylatoxin causing mast cell degranulation and vascular permeability) and C3b (an opsonin deposited on targets for phagocytosis and further complement amplification). C5 (complement component 5) convertases (formed by addition of C3b to either C3 convertase) cleave C5 into C5a (a potent anaphylatoxin and chemotactic factor) and C5b, which initiates MAC assembly (C5b-9), leading to osmotic lysis of target cells.16
Complement Regulation and Disease Mechanisms. Host cells are protected from complement attack by a suite of regulatory proteins: CD55 (decay-accelerating factor, DAF), which accelerates decay of C3 and C5 convertases; CD59 (protectin), which blocks MAC assembly by preventing C9 (complement component 9) incorporation; factor H, which acts as a co-factor for factor I-mediated cleavage of C3b and C4b; and C1-inhibitor (C1-INH), which inactivates C1r, C1s, and MASPs. Genetic or acquired deficiencies in these regulatory proteins lead to pathological complement activation. Paroxysmal nocturnal hemoglobinuria (PNH) is caused by somatic mutations in the PIGA (phosphatidylinositol glycan class A) gene in hematopoietic stem cells, impairing glycosylphosphatidylinositol (GPI) anchor biosynthesis and thus depleting GPI-anchored complement regulators CD55 and CD59 from blood cell surfaces, rendering PNH erythrocytes and platelets susceptible to spontaneous complement-mediated hemolysis and thrombosis. Atypical hemolytic uremic syndrome (aHUS) is driven by uncontrolled alternative pathway activation due to mutations in factor H, factor I, CD46 (MCP), or C3 itself. C3 glomerulopathy results from complement dysregulation in the kidney. Hereditary angioedema (HAE) results from C1-INH deficiency, causing uncontrolled classical pathway and contact activation with bradykinin generation and recurrent attacks of subcutaneous and submucosal edema.1617
C5 Inhibitors: Eculizumab and Ravulizumab. Eculizumab is a humanized monoclonal IgG2/IgG4 antibody that binds C5 with high affinity, preventing its cleavage into C5a and C5b and thus blocking MAC formation. By acting at C5, eculizumab preserves upstream complement opsonization (C3b deposition) while eliminating the terminal lytic and inflammatory consequences. Eculizumab is approved for PNH, aHUS, generalized myasthenia gravis (gMG) with anti-AChR antibodies, and neuromyelitis optica spectrum disorder (NMOSD) with anti-AQP4 antibodies. The most serious adverse effect is susceptibility to encapsulated bacteria, particularly Neisseria meningitidis; meningococcal vaccination (MenACWY and MenB) is mandatory at least two weeks before initiation, and many centers continue prophylactic penicillin indefinitely. The main limitation of eculizumab is its short half-life requiring intravenous infusions every two weeks after a loading phase. Ravulizumab is a next-generation C5 inhibitor engineered from eculizumab with three amino acid substitutions that extend the half-life approximately four-fold, allowing maintenance dosing every eight weeks; it is approved for the same indications as eculizumab with equivalent efficacy and improved dosing convenience.17
C3 Inhibitors and Factor Pathway Inhibitors. Pegcetacoplan is a PEGylated cyclic peptide C3 inhibitor that binds C3 and C3b, blocking all three complement pathways upstream of C5 and preventing both C3-fragment-mediated extravascular hemolysis and MAC-mediated intravascular hemolysis. It is approved for PNH in adults who are inadequately controlled on eculizumab or ravulizumab and may be superior to C5 inhibitors in patients who have significant C3-mediated extravascular hemolysis despite C5 blockade. Iptacopan is an oral factor B inhibitor approved for PNH; factor B is specific to the alternative pathway, and its inhibition blocks alternative pathway amplification and is effective for PNH management as a once-daily oral agent. Berotralstat and garadacimab are factor XIIa inhibitors used for HAE prophylaxis, acting upstream of C1-INH to prevent contact activation. C1-INH concentrates (plasma-derived and recombinant) are used for acute HAE attacks and prophylaxis by restoring the natural inhibitor of classical pathway initiation and contact system activation; they treat HAE by reducing bradykinin generation rather than by complement inhibition per se, though both mechanisms are downstream of C1-INH deficiency.16
Eculizumab/ravulizumab (anti-C5): PNH, aHUS, gMG (anti-AChR), NMOSD (anti-AQP4). Mandatory meningococcal vaccination before start; continue penicillin prophylaxis. Ravulizumab advantage: every-8-week dosing vs. every-2-week (eculizumab). Pegcetacoplan (C3 inhibitor): PNH inadequately controlled on C5 inhibitor; blocks extravascular hemolysis. Iptacopan (oral factor B inhibitor): PNH; once-daily oral, alternative pathway selective. C1-INH concentrate (plasma or recombinant): acute HAE and prophylaxis; reduces bradykinin-mediated angioedema, not direct complement suppression. Icatibant (bradykinin B2 receptor antagonist): acute HAE attacks. Lanadelumab (anti-plasma kallikrein mAb): HAE prophylaxis.
The immunopharmacology landscape has expanded dramatically over the past three decades from a handful of broadly immunosuppressive agents to a sophisticated toolkit of targeted therapies capable of modulating specific immune pathways with unprecedented precision. This section provides a practical orientation to the major drug classes covered across the five modules of this chapter, their mechanistic foundations, and their clinical positioning relative to one another and to content covered elsewhere in this series.
Broad Immunosuppressants: The Historical Foundation. The first generation of clinically effective immunosuppressive drugs acted through broad mechanisms affecting multiple aspects of immune function. Corticosteroids bind the intracellular glucocorticoid receptor (GR) and modulate gene transcription through both genomic (GRE (glucocorticoid response element) transactivation of anti-inflammatory genes; transrepression of nuclear factor kappa B (NF-kB) and activator protein 1 (AP-1)) and non-genomic mechanisms, suppressing virtually every arm of the immune response in a dose-dependent fashion. Calcineurin inhibitors (cyclosporine and tacrolimus) block T-cell interleukin-2 (IL-2) production by inhibiting calcineurin-mediated nuclear factor of activated T cells (NFAT) dephosphorylation and nuclear translocation. Antimetabolites (azathioprine, mycophenolate mofetil) impair lymphocyte proliferation by depleting purine or pyrimidine precursors essential for deoxyribonucleic acid (DNA) synthesis. mTOR inhibitors (sirolimus, everolimus) block T-cell proliferative responses to IL-2 through mTORC1 inhibition. These agents form the backbone of transplant immunosuppression and are covered in depth in Module 02.12
Biologic Targeted Therapies. The introduction of therapeutic monoclonal antibodies and fusion proteins beginning in the late 1990s transformed the treatment of autoimmune and inflammatory diseases. Biologic drugs achieve selectivity by targeting individual cytokines, cytokine receptors, cell surface molecules, or co-stimulatory pathways with high affinity and specificity. Key structural classes include fully human IgG monoclonal antibodies (adalimumab, ustekinumab, guselkumab), humanized monoclonal antibodies (tocilizumab, mepolizumab), chimeric monoclonal antibodies (infliximab, rituximab), Fab fragments (certolizumab pegol), and fusion proteins that combine receptor extracellular domains with IgG Fc regions (etanercept, abatacept, rilonacept). Naming conventions reflect the structural class: fully human antibodies end in -umab; humanized antibodies end in -zumab; chimeric antibodies end in -ximab; fusion proteins end in -cept. Module 03 covers the major biologic immunosuppressants including tumor necrosis factor (TNF) inhibitors, interleukin-1 (IL-1) antagonists, interleukin-6 (IL-6) pathway inhibitors, interleukin-17/interleukin-23 (IL-17/IL-23) axis inhibitors, and B-cell targeted therapies.89
Small Molecule Targeted Immunomodulators. The development of small molecules capable of selectively inhibiting specific kinases in immune signaling pathways has produced a second generation of targeted oral immunotherapy. Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, upadacitinib, ruxolitinib, deucravacitinib) interrupt cytokine signaling at the intracellular level, offering oral administration, rapid onset, and short half-lives that facilitate dose adjustment but also require more frequent dosing than biologic agents. Co-stimulation blockers (abatacept, belatacept) interrupt the CD28-CD80/86 (cluster of differentiation 28 and its co-stimulatory ligands CD80/CD86) signal required for full T-cell activation without depleting T cells. Integrin antagonists (natalizumab, vedolizumab) prevent lymphocyte trafficking to inflammatory sites. Sphingosine-1-phosphate (S1P) receptor modulators (fingolimod, siponimod, ozanimod) sequester lymphocytes in lymph nodes by functionally antagonizing the S1P receptor responsible for lymphocyte egress. Phosphodiesterase 4 (PDE4) inhibitors (apremilast) reduce cytokine production without broad immunosuppression. These agents are covered in Module 04.1415
Immunostimulatory Agents. Immunopharmacology encompasses not only immunosuppression but also the pharmacological augmentation of immune function. This includes cytokine therapeutics that enhance specific immune responses (IL-2 for T-cell expansion, IFN-alpha for antiviral and anti-tumor activity, interferon-gamma (IFN-gamma) for macrophage activation in chronic granulomatous disease (CGD)), hematopoietic growth factors that restore depleted immune cell populations (G-CSF, GM-CSF), intravenous immunoglobulin that modulates Fc receptor signaling and provides passive immunity, and vaccine adjuvants that optimize the innate immune environment to maximize adaptive responses. Pharmacological approaches to primary immunodeficiency treatment including enzyme replacement, gene therapy, and immunoglobulin replacement constitute another important dimension of the immunostimulatory pharmacology framework. Module 05 covers these topics in depth. Cancer immunotherapy through checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapy represents a further dimension of immunostimulation covered comprehensively in Chapter 34 (ACD2-04); the mechanistic foundations introduced in this module provide the conceptual framework for that material.1011
Cross-Cutting Principles for Clinical Practice. Several overarching principles apply across all immunopharmacology drug classes and are essential for safe prescribing. First, screening for latent infections before initiating any immunosuppressive therapy is mandatory: tuberculosis screening (tuberculin skin test or interferon-gamma release assay) and hepatitis B serology (HBsAg, anti-HBc) are required before all biologics and JAK inhibitors; hepatitis C, human immunodeficiency virus (HIV), and varicella-zoster virus (VZV) serology should be considered based on individual risk. Second, live vaccines are contraindicated in patients receiving immunosuppressive biologics or small molecules due to the risk of vaccine-strain disseminated infection; vaccination schedules should be updated ideally four to six weeks before initiating therapy, and inactivated vaccines can be given during therapy though immunogenicity may be reduced. Third, the timing of biologic therapy relative to surgery requires individualized assessment; most guidelines suggest withholding biologics for one to two half-lives before elective surgery to reduce infection risk, though the evidence base for this practice is limited. Fourth, the concept of the therapeutic window differs in a clinically critical way for immunosuppressants compared to other drug classes: under-immunosuppression risks rejection or disease flare, while over-immunosuppression risks opportunistic infection and malignancy, and the balance must be continuously reassessed throughout the treatment course.212
Module 01 (this module): Immune system foundations, cytokine networks, JAK-STAT signaling, complement pharmacology, drug class orientation. Module 02: Calcineurin inhibitors, mTOR inhibitors, antimetabolites, corticosteroids, transplant immunosuppression protocols. Module 03: Biologic immunosuppressants — TNF inhibitors, IL-1/IL-6/IL-17/IL-23 antagonists, B-cell therapies, dupilumab and eosinophil-targeted biologics. Module 04: JAK inhibitors (clinical use, safety), co-stimulation blockade, integrin antagonists, S1P modulators, PDE4 inhibition. Module 05: Immunostimulation — cytokine therapeutics, G-CSF/GM-CSF, IVIG, vaccine pharmacology, primary immunodeficiency treatment. Cross-reference: checkpoint inhibitors and CAR-T therapy → Chapter 34, Module ACD2-04.
Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease. 9th ed. New York: Garland Science; 2017. ISBN 9780815345053.
doi:10.1201/9781315533247Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006;24(3):233-238.
doi:10.1016/j.immuni.2006.03.001Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.
doi:10.1056/NEJMoa1707914Sanz I, Lund FE. B cell responses to pathogens and vaccines in health and disease. J Immunol. 2020;205(2):293-301.
doi:10.4049/jimmunol.2000291Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-384.
doi:10.1038/ni.1863Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674-678.
doi:10.1038/nature07317Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-265.
doi:10.1146/annurev.immunol.021908.132715Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-279.
doi:10.1016/j.pharmthera.2007.10.001Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295.
doi:10.1101/cshperspect.a016295Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38(1):13-25.
doi:10.1016/j.immuni.2013.01.004Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
doi:10.1038/nrd4624Miossec P, Kolls JK. Targeting IL-17 and Th17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763-776.
doi:10.1038/nrd3794Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667-679.
doi:10.1182/blood-2016-10-695940O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311-328.
doi:10.1146/annurev-med-051113-024537Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326.
doi:10.1056/NEJMoa2109927Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785-797.
doi:10.1038/ni.1923Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530-539.
doi:10.1182/blood-2018-09-876136